Albatroz Therapeutics announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
[Albatroz Therapeutics (JoplingGlobe)]